Related Experiment Video

Updated: Nov 27, 2025

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.4K

ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway

Oded Jacobi1, Jeffrey S Ross2, Tal Goshen-Lago3

  • 1Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Petah Tiqwa, Israel, jacobi.oded@gmail.com.

Oncology Research and Treatment
|December 6, 2020
PubMed
Abstract

Insights

Cholangiocarcinoma (CCA) genomic analysis reveals frequent ERBB/EGFR pathway alterations. Targeted therapy, including anti-HER2 agents, showed clinical benefit, suggesting these alterations are clinically significant for CCA patients.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Current cholangiocarcinoma (CCA) chemotherapy offers limited survival benefits.
  • Genomic profiling of CCA has identified potential therapeutic targets.
  • Efficacy data for targeted therapies in CCA remain scarce.

Purpose of the Study:

  • To characterize the genomic landscape of cholangiocarcinoma (CCA) patients.
  • To focus on the ERBB/EGFR pathway and its alterations.
  • To assess the response of CCA patients with ERBB/EGFR aberrations to anti-HER2 agents.

Main Methods:

  • Next-generation sequencing (NGS) was performed on 1,863 intrahepatic CCA (IHCC) and extrahepatic CCA (EHCC) tissue samples.
  • Somatic aberrations, particularly in the ERBB/EGFR pathway, were identified.
  • Clinical outcomes of patients treated with anti-HER2 agents were evaluated.

Main Results:

  • A high prevalence of ERBB alterations was observed in CCA (IHCC: 4.2%, EHCC: 9.7%).
  • ERBB2 mutations and copy number amplifications were frequent in both IHCC and EHCC subtypes.
  • Three EHCC patients with ERBB/EGFR aberrations treated with anti-HER2 agents (neratinib or trastuzumab combination) achieved disease stabilization and clinical benefit.

Conclusions:

  • The genomic profile of cholangiocarcinoma (CCA) frequently includes targetable ERBB/EGFR pathway alterations.
  • These findings suggest that ERBB/EGFR pathway alterations have clinical significance in CCA management.
  • Targeted therapies may offer a promising treatment avenue for selected CCA patients.
Keywords:
CholangiocarcinomaERBB2HER2Targeted therapy

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.0K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K